{
    "clinical_study": {
        "@rank": "4990", 
        "acronym": "BELIEVE III", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo infused for up to 72 hours IV"
            }, 
            {
                "arm_group_label": "CD-NP 5 ng/kg/min", 
                "arm_group_type": "Active Comparator", 
                "description": "CD-NP 5 ng/kg/min infused for up to 72 hours IV"
            }, 
            {
                "arm_group_label": "CD-NP 10 ng/kg/min", 
                "arm_group_type": "Placebo Comparator", 
                "description": "CD-NP 10 ng/kg/min infused for up to 72 hours IV"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary endpoint is to assess the safety and tolerability of CD-NP with the incidence of\n      symptomatic hypotension being one of the key safety variables."
        }, 
        "brief_title": "CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Anterior ST-Elevation Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction", 
                "Anterior Wall Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a \"proof of concept\", randomized, double-blind, placebo controlled study. The study\n      population will include 60 patients admitted with a first time ST elevation anterior STEMI\n      as diagnosed by the following criteria: a) Significant chest discomfort and /or shortness of\n      breath; b) ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial\n      leads; c) Successful reperfusion therapy (>TIMI grade 2 flow) either with thrombolytics or\n      PTCA within 24 hours of onset of symptoms as documented by coronary angiography; and d) No\n      previous history of an anterior AMI or previous ECG suggesting an old anterior AMI.\n\n      Patients will be randomized to one of two doses of CD-NP (5 ng/kg/min and 10 ng/kg/min) or\n      placebo continuous infusion for up to 72 hours in a 1:1:1 manner. All patients will receive\n      other standard medical therapies as determined appropriate by the physician and in\n      accordance to the ACC/AHA guidelines"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  first time ST elevation anterior STEMI\n\n          -  Significant chest discomfort and /or shortness of breath\n\n          -  ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads\n\n          -  Successful reperfusion therapy (>TIMI grade 2 flow) either with thrombolytics or PTCA\n             within 24 hours of onset of symptoms as documented by coronary angiography\n\n          -  No previous history of an anterior AMI or previous ECG suggesting an  old anterior\n             AMI.\n\n        Exclusion Criteria:\n\n          -  Cardiogenic shock, acute heart failure or hypotension (Systolic BP < 90 mmHg)\n\n          -  Previous MI\n\n          -  Previous known decreased EF < 40%\n\n          -  Atrial Fibrillation\n\n          -  Persistent signs and symptoms of Post MI ischemia\n\n          -  Requirement of pressors for maintenance of blood pressure.\n\n          -  Intra-aortic blood pump use\n\n          -  Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or\n             obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary\n             hypertension.\n\n          -  Severe congenital heart diseases\n\n          -  Sustained ventricular tachycardia or ventricular fibrillation\n\n          -  Second or third degree heart block without a permanent cardiac pacemaker\n\n          -  Stroke within 3 months or other evidence of significantly compromised CNS perfusion\n\n          -  Total bilirubin of > 2.5 mg/dL or other liver enzymes >2.5 times the upper limit of\n             normal\n\n          -  Patients with calculated GFR <30 ml by MDRD equation or those with acute kidney\n             injury as defined by an increase of plasma creatinine of 0.5 mg/dL from a plasma\n             creatinine measured within the last 7 days\n\n          -  Serum sodium of < 125 mEq/dL or > 160 mEq/dL\n\n          -  Serum potassium of < 3.0 mEq/dL or > 5.8 mEq/dL\n\n          -  Hemoglobin < 8.5 gm/dl\n\n          -  Other acute or chronic medical conditions or laboratory abnormality which may\n             increase the risks associated with study participation or may interfere with\n             interpretation of the data\n\n          -  Received an investigational drug within 1 month prior to dosing\n\n          -  Female subject who is pregnant or breastfeeding\n\n          -  Unable to undergo cardiac MRI\n\n          -  In the opinion of the investigator, is unlikely to comply with the study protocol or\n             is unsuitable for any reasons"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071602", 
            "org_study_id": "12-006317"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "CD-NP 5 ng/kg/min", 
                "CD-NP 10 ng/kg/min"
            ], 
            "description": "Randomized 1:1:1", 
            "intervention_name": "CD-NP", 
            "intervention_type": "Drug", 
            "other_name": "Cenderitide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Heart attack", 
            "Myocardial Infarction", 
            "STEMI"
        ], 
        "lastchanged_date": "February 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224"
                    }, 
                    "name": "Mayo Clinic in Florida"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic in Rochester"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study", 
        "overall_contact": {
            "email": "polk.lynn@mayo.edu", 
            "last_name": "Lynn E Polk, RN", 
            "phone": "507-255-2527"
        }, 
        "overall_contact_backup": {
            "email": "woltman.cindy@mayo.edu", 
            "last_name": "Cindy M Woltman, RN", 
            "phone": "507-266-4095"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "John Schirger, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with symptomatic hypotension", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to 30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071602"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "John A. Schirger", 
            "investigator_title": "Princpal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Comparison of LV function improvement between placebo vs. CD-NP groups", 
                "safety_issue": "No", 
                "time_frame": "baseline to 30 days"
            }, 
            {
                "measure": "Exploratory analyses of Major Adverse Cardiovascular Events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}